GA II
Latest Information Update: 19 Jan 2018
At a glance
- Originator Transkaryotic Therapies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 31 Oct 2003 Discontinued - Phase-I for Metabolic disorders in USA (unspecified route)
- 31 Dec 2001 Phase-I clinical trials in Metabolic disorders in USA (unspecified route)
- 10 Jan 2000 Preclinical development for Metabolic disorders in USA (Unknown route)